Introduction {#S1}
============

Sleep is a highly conserved behavior that is vital to survival among all living organisms with a nervous system, from worms to humans. Chronic sleep loss is linked to a wide range of deleterious physiologic changes, such as altered food intake, weight loss or gain, skin lesions, compromised thermoregulation, and even death ([@B105]; [@B120]). Humans spend roughly one-third of their lives asleep. While we know why we eat, drink, and mate, we do not yet know why we sleep. The neuroscience community has therefore increased efforts to gain knowledge of the physiologic function of sleep.

During sleep, cortical neurons alternate between periods of firing and periods of silence. The switching between the two states, also known as ON and OFF states, is widely synchronized across neurons and represented by slow wave activity (SWA) in encephalography. SWA is observed as slow, oscillatory neocortical activity (0.5--4.5 Hz) that intensifies in correlation with wake duration and declines during sleep, but is expressed only during slow wave sleep (SWS). Because SWS-SWA increases as sleep loss is prolonged and decreases as sleep progresses, it is widely used as a marker of mammalian sleep homeostasis. The rates of SWA build-up and decay can be altered by extreme sleep loss or by pharmacologic or genetic manipulations in mammals, especially those affecting adenosine systems of the central nervous system (CNS). The adenosine system can also affect the gating of SWS-SWA expression by modulating the arousal level, thereby altering the duration of time during which sleep homeostasis and function can occur.

Adenosine is the key building block of every cell's energy source, i.e., adenosine triphosphate (ATP), and the related adenosine mono- and di-phosphates (AMP and ADP, respectively). Adenosine fulfills a wide range of physiologic and pathophysiologic functions ([@B43]). In the nervous system, adenosine acts as a neuromodulator through metabotropic receptors. Although adenosine acts on four evolutionarily well-conserved receptors present on most cells, it is believed to modulate sleep need and arousal by acting through A~1~ and A~2A~ receptors (A~1~Rs and A~2A~Rs), respectively.

In light of the emerging roles of adenosine and its receptors in regulating different aspects of sleep, we propose a model for the gating and function of sleep. In our model, A~2A~Rs allow the brain to sleep, i.e., these receptors provide sleep gating, whereas A~1~Rs modulate the function of sleep, i.e., these receptors are essential for the expression and resolution of the sleep need.

Aspects of Sleep/Wake Regulation {#S2}
================================

Humoral Theory of Sleep-Wake Regulation {#S2.SS1}
---------------------------------------

The humoral theory of sleep-wake regulation posits that during wakefulness, one or more endogenous somnogenic factors is produced and accumulated. Brain activity decreases when the concentration of somnogenic substances increases to a certain threshold. These substances are gradually metabolized during sleep, which leads to a return to the waking state. [@B106] hypothesized that sleep is regulated by humoral factors; i.e., excess water accumulation due to oxidative processes in nerve cells during wakefulness depresses neuronal excitability and removal of the excess water during sleep restores full brain activity, resulting in wakefulness. A few years later, [@B61] and [@B76] independently demonstrated the existence of sleep-promoting hypnogenic substances, also known as "hypnotoxins," in the cerebrospinal fluid of sleep-deprived dogs ([@B71]; [@B60]).

The hypnotic effect of adenosine in the mammalian brain was discovered in 1954 ([@B37]). Adenosine as a neuromodulator with somnogenic properties should thus be classified as a sleep substance. Extensive evidence also suggests that components of the immune system, such as pro-inflammatory cytokines ([@B70], [@B69]; [@B86], [@B87]; [@B68]) \[for review, see ([@B67])\] and prostaglandins ([@B135]; [@B75]; [@B134]; [@B93]) \[for review, see ([@B134])\], are interrelated with the regulation of sleep. The involvement of other putative hypnogenic substances, including anandamide ([@B49]), urotensin-II peptide ([@B59]), and the *Drosophila* peptide NEMURI ([@B132]), is also implicated in the sleep process.

Circuit-Based Theories of Sleep-Wake Regulation {#S2.SS2}
-----------------------------------------------

A slow humoral process, however, cannot sufficiently explain the reversibility of sleep, especially rapid transitions from sleep to wake in response to external stimuli. Experimental work by Constantin von Economo in the early 20th century produced findings that inspired circuit-based theories of sleep/wake regulation. In 1916, von Economo began to see patients with a new type of encephalitis eventually referred to as encephalitis lethargica or von Economo's sleeping sickness. The disorder was characterized by lesions in the anterior hypothalamus leading to prolonged insomnia or lesions at the junction of the brainstem and forebrain leading to prolonged sleepiness ([@B138]; [@B33]). Von Economo concluded that these brain areas must play a role in sleep/wake regulation. The "passive theory," which dominated in the 1940/1950s, suggested that sleep occurs passively due to decreased activity of the brainstem reticular formation ([@B18]; [@B85]). Importantly, this "passive theory" implicates a necessary active neuronal modulation to maintain a behavioral state of wake via the ascending reticular activating system. Although overly restrictive to the reticular activating system with regard to the wake-modulatory components, the principle of a necessary activation for wake cannot be ruled out; nor can an active sleep-promoting modulation be ruled out, as these are not mutually exclusive types of modulation.

Many decades later, neurons that are active when animals sleep were identified in the ventrolateral preoptic area (VLPO) near the third ventricle in the anterior part of the hypothalamus ([@B119]; [@B22]). Studies demonstrated that sleep is promoted by projections from the GABAergic preoptic area (POA), including the VLPO, to the tuberomammillary nucleus (TMN) in the posterior hypothalamus ([@B118]; [@B22]), which contains neurons that produce histamine, a neurotransmitter having an important role in arousal ([@B57]; [@B51]; [@B89]). These findings provided strong evidence of sleep control by the POA-TMN neural pathway.

Neural circuits in the brainstem and basal ganglia also regulate sleep/wake behavior. The parafacial zone (PZ) in the medulla contains sleep-promoting GABAergic neurons ([@B3], [@B2]) that project to the parabrachial nucleus (PB), a critical nucleus for cortical activation as lesions of the PB result in a comatose state ([@B47]).

More recently, the involvement of dopaminergic neurons in the ventral tegmental area (VTA) was strongly implicated in the arousal effect ([@B32]; [@B91]). A role for dopamine in arousal is also supported by evidence that amphetamine, which induces the release of monoamines (including dopamine), increases alertness and psychomotor performance in sleep-deprived individuals ([@B15]). Dopamine transporters are necessary for the wake-promoting effects of amphetamine ([@B143]). Ablating or suppressing GABAergic neurons in the ventral medial midbrain/pons (VMP), including the VTA, produces wakefulness and prevents sleep mainly through dopaminergic systems ([@B128]; [@B146]). Furthermore, the ability of dopamine neurons in the VTA to promote wakefulness is at least in part mediated by projections to the nucleus accumbens (NAc; [@B32]). Medium spiny GABAergic neurons in the NAc can be divided into two groups that respond differentially to stimulation by dopamine or adenosine. Direct pathway neurons express excitatory dopamine D~1~ receptors and inhibitory adenosine A~1~Rs, whereas neurons of the indirect pathway express inhibitory dopamine D~2~ receptors and excitatory A~2A~Rs. In fact, recent studies showed that NAc direct pathway neurons induce wakefulness ([@B79]) and A~2A~R-expressing indirect pathway neurons strongly induce SWS ([@B92]). The indirect pathway neurons in the NAc produce sleep by inhibiting the ventral pallidum (VP) in the basal forebrain (BF), although these neurons also have sparse to moderate projections to other well-known arousal-promoting areas, such as the lateral hypothalamus, which produces orexin, the TMN, and the VTA. Interestingly, chemogenetic activation of the BF, including the VP, largely reduces sleep ([@B4]).

Altogether, it is impossible to abolish sleep completely by lesioning the afore-mentioned inhibitory circuits, including the POA-TMN, PZ-PB, and NAc-VP pathways, making it unlikely that the regulation of sleep time depends on a single center (i.e., a master switch for sleep in the brain may not exist). On the contrary, the existence of various neural circuits controlling sleep suggests that sleep is gated by different processes. All of these sleep/wake circuits clearly modulate an animal's level of arousal (i.e., vigilance) to determine the behavioral state and GABA is the key neurotransmitter for promoting the transition from wake to sleep and the duration of sleep. For example, the observation that the level of wakefulness is regulated by VMP GABAergic neurons ([@B128]) indicates the ability of the brain to adapt an animal's sleep/wake time to its behavior.

The transition from waking to sleep may be essential, at least under physiologic conditions, for the facilitation of sleep function to occur. A sufficiently increased level of arousal, as may be experimentally or environmentally induced, prevents sleep occurrence and, accordingly, sleep function. The resulting increase in sleep need is normally reflected by an increase in SWA in the ensuing sleep episode. During this ensuing episode, SWS-SWA resolves toward a non-sleep deprived baseline and the threshold for arousal to waking decreases. As a matter of fact, local sleep, i.e., a phenomenon in which discrete regions of cortical neurons go "offline" similar to during sleep, but other regions do not, is insufficient for sleep function to occur ([@B139]), most likely as a result of the brain's massive interconnectivity. Thus the integration of local sleep events into a global sleep state is necessary for effective sleep function, even at a local level.

Homeostatic Regulation of Sleep (Two-Process Model) {#S2.SS3}
---------------------------------------------------

In 1982, Alexander Borbély at the University of Zürich in Switzerland proposed a two-process model of sleep regulation ([@B16]) that currently prevails as a major conceptual framework in sleep research. In a simplified version of the two-process model of sleep regulation, sleep propensities in homeostatic and circadian processes are commonly plotted against the time of day and interactions of the two processes determine the cardinal aspects of sleep regulation. The "homeostatic" process is controlled by the sleep pressure or need that builds up during the waking period and dissipates during sleep. In contrast, the "circadian" process, i.e., the sleep/wake cycle during the day and night, is controlled by a circadian pacemaker or biologic clock. Although it was originally hypothesized that the circadian process is independent of prior sleep and waking, experiments in mice lacking clock genes revealed that clock gene knockout (KO) disrupts not only circadian processes, but also sleep homeostatic processes ([@B40]). This suggests overlapping functions for the circadian genes in sleep homeostatic control.

Consistent with the two-process model, a homeostatic response to sleep loss, namely sleep rebound in an animal after sleep deprivation, is considered an essential criterion of sleep. Rebound can reflect an increase in SWS-SWA power and/or an increase in SWS duration along with an increase in consolidation. Of these two rebound parameters, SWS-SWA is better correlated with prior waking time. Although a rebound increase in SWA during SWS is often associated with an increase in SWS time or consolidation, its occurrence may be dissociated from an effect on sleep time ([@B30]; [@B11]; [@B126]). Importantly, SWA during SWS is considered to be an indicator of sleep intensity ([@B17]), providing a dimension beyond time in the recovery from prolonged waking. Interestingly, although sleep rebound is widely observed after sleep loss, some species skip sleep in favor of migration, mating, or other social interactions and do not catch up on lost sleep ([@B9]; [@B104]; [@B80]; [@B46]; [@B131]; [@B77]). Recently, scientists at the Imperial College London demonstrated that male flies in the presence of another male fly undergo sleep loss that results in a sleep rebound once the male intruder is removed, whereas a resident fly also loses sleep in the presence of a female fly, but shows no sleep rebound when the female fly is removed ([@B7]), suggesting that sexual arousal in flies prevents a homeostatic response to sleep loss. Altogether, there is ample evidence in nature challenging the view that sleep rebound is an inescapable outcome of sleep loss. Nevertheless, the "rebound" in these cases refers only to sleep duration and not to SWS-SWA intensity. This potential dissociation of SWS duration from SWS-SWA expression (i.e., SWS duration may not reflect the SWA changes shaping sleep homeostasis) suggests that it may not be possible to fully interpret rebound sleep or the lack thereof in the absence of SWS-SWA assessment.

Another limitation of the two-process model is that it defines circadian input as the only allostatic component that drives the balance between waking and sleep. Sleep/wake behavior is also influenced by cognitive and emotional factors ([@B110]; [@B38]; [@B88]) or other basic drives, such as a lack of food, predator confrontation, mating pressure, and seasonal migration ([@B144]; [@B20]). The mechanisms by which motivational stimuli or stressors interact with sleep/wake behavior are not easily accounted for by the two-process model. On the other hand, if the exceptional conditions mentioned above primarily affect arousal level and thus gating of sleep, then sleep homeostasis, conceptualized as "process S" in the two-process model, may still occur. Sleep homeostasis, although related to arousal (sleep need can dissipate to the largest extent only during sleep) appears to follow an exponential rate of decay ([@B41]; [@B10]). With greater sleep need, there is greater rebound SWS-SWA, but the rate of decay is slowed, further enhancing the amount of SWS-SWA expressed ([@B10]).

The increased sleep duration and consolidation associated with increased sleep need may reflect a decreased level of arousal needed for waking although both external sensory input as well as the internal state (likely to include circadian drive, need for food, predator threat, sex drive, etc.) remain as effective determinants. Accordingly, level of arousal and sleep duration are dynamic, relying on the integration of multiple factors in addition to previous waking time.

Sleep as a State of Adaptive Inactivity {#S2.SS4}
---------------------------------------

An alternative view proposes that sleep enforces adaptive inactivity to conserve energy when activity is not beneficial ([@B121]). The wide variability in sleep duration across the animal kingdom ([@B100]) suggests the sleep amount of an animal may be adapted to the species' behavior that is critical for survival. Consequently, animals may have the ability to dispense with sleep when varying ecologic demands favor wakefulness; e.g., the ability of male pectoral sandpipers to maintain high neurobehavioral performance despite greatly reduced sleeping time when competing for mating opportunities in a short annual window of female fertility ([@B77]) may contradict the notion that decreased performance is an inescapable outcome of sleep loss. A model of sleep as a state of adaptive inactivity challenges the hypothesis that the sleep state persists because it has a vital physiologic function and proposes that sleep has not evolved for what happens when we are asleep, but rather for the energy-saving absence of activity during sleep. The magnitude of energy savings gained through sleep is still unknown, although a new framework for determining relative energy savings during sleep was recently described ([@B114]).

The teleological problem of sleep function may arise from the presumption of sleep's evolution from a default state of waking. Humans are likely biased toward this presumption by the egocentricity of waking consciousness. The adaptive inactivity model could be modified by reorientation of the question "why do we sleep" to "why do we wake?" In this model, sleep is considered the state that facilitates vegetative functions like anabolism and replacement of proteins, complex carbohydrates, and complex lipids and organelles. The vegetative functions are clearly not inactivity or passive in terms of energy conservation. On the contrary, there is evidence for increased energy utilization in sleep, such as ATP mobilization and AMP dephosphorylation ([@B31]). Moreover, the cellular metabolism of brain tissue does not coincide with the systemic eating and digestion of food. From this perspective, an organism is driven to waking primarily by non-vegetative, life-essential pursuits, such as foraging for food, avoiding predators, and, occasionally, sex, along with an integrated circadian timer (also controlling arousal). This model is thus consistent with an active drive or activating system needed to maintain wake.

Dissociation of the Arousal State and Sleep Homeostasis {#S2.SS5}
-------------------------------------------------------

An increase in the response threshold to external stimuli is a core feature of sleep ([@B147]) and is critical for defining sleep in animals that lack a cortex (for review, see [@B54]). Prolonged waking by sleep deprivation increases the arousal threshold during subsequent sleep ([@B141]; [@B14]), and stronger stimuli are necessary to prevent sleeping/prolong waking ([@B12]). As with spontaneous waking, arousal during sleep deprivation is modulated by internal and external stimuli, but within the context of sleep deprivation the arousal threshold is typically increased. Arousal-related brain regions show greater activity, as measured by c-fos, under sleep deprivation mediated by exposure to novel environments or social interaction compared with gentle handling alone ([@B26]). Furthermore, the nature of the homeostatic response to prolonged waking varies across development with increases in sleep time preceding the appearance of increased SWA power ([@B39]). Finally, SWA power, commonly used as an indicator of homeostatic sleep need, is increased within waking during prolonged sleep deprivation ([@B41]; [@B139]), but the relationship between SWA and sleep homeostasis can be dissociated in pathologic disorders. SWA power is increased during waking and rapid eye movement (REM) sleep in Alzheimer's disease ([@B53]; [@B62]); whereas SWA is increased during waking but decreased during sleep in schizophrenia ([@B64]; [@B55]; [@B36]). Conversely, faster EEG activity, such as beta and gamma rhythms commonly used as an indicator of arousal, is high during sleep in a subset of insomniacs ([@B97]; [@B27]).

Adenosine and Sleep {#S3}
===================

Adenosine Metabolism and Levels During Sleep and Wakefulness {#S3.SS1}
------------------------------------------------------------

Hydrolysis of AMP and S-adenosylhomocysteine (SAH) produces adenosine ([@B115]; [@B42]). Adenosine is generated from SAH by SAH hydrolase, which also acts to trap adenosine in the presence of excess L-homocysteine. This takes place intracellularly and the bidirectional actions of the enzyme ensure the constant presence of a particular concentration of adenosine in the cell. Whether SAH hydrolase is involved in generating adenosine in the brain, however, is controversial ([@B73]). Adenosine is formed intracellularly and extracellularly from 5′-AMP by different 5′-nucleotidase (5′-NT) ([@B149]). A cascade of actions by an ecto-5′-NT, together with ecto-ATPases, terminates the action of ATP as extracellular signaling molecules ([@B149], [@B150]; [@B145]; [@B66]).

High adenosine levels are reduced by the actions of adenosine deaminase (ADA), or are taken up by cells where adenosine is rapidly phosphorylated to AMP by adenosine kinase (AdK), an enzyme that effectively controls the intracellular adenosine concentration ([Figure 1](#F1){ref-type="fig"}; [@B45]; [@B89]; [@B95]). Importantly, AdK binds a molecule of ATP and adenosine, catalyzes the transfer of a phosphate group from ATP to adenosine and produces ADP and AMP. As a result, the rate of adenosine metabolism is reflected by the \[ATP\]/\[ADP\]\[AMP\] ratio, linking the rate of adenosine metabolism to the metabolic state of the cell. In the adult CNS, AdK expression occurs predominately in the glia ([@B125]), and thus the concentration of adenosine is controlled by the metabolic state of the glia.

![Control of the adenosine concentration by the metabolic state of astrocytes. Adenosine taken up by astrocytes is rapidly phosphorylated to AMP by adenosine kinase (AdK), an enzyme expressed predominantly in glia in the adult CNS. AdK effectively controls the intracellular adenosine concentration by catalyzing the transfer of a phosphate group from ATP to adenosine to produce ADP and AMP. As a result, the rate of adenosine metabolism is reflected by the \[ATP\]/\[ADP\]\[AMP\] ratio, linking the rate of adenosine metabolism to the metabolic state of the cell. Equilibrative nucleoside transporters (ENT) bi-directionally regulate the concentration of adenosine available to pre- and post-synaptic A~1~Rs and A~2A~Rs. Other abbreviations used: 5′-NT, 5′-nucleotidase; ADA, adenosine deaminase.](fnins-13-00740-g001){#F1}

Bi-directional equilibrative nucleoside transporters regulate the concentration of adenosine available to cell surface adenosine receptors ([@B95]; [@B28]). Therefore, adenosine levels are dependent on the formation and removal of extracellular adenosine. Extracellular adenosine levels are low under basal conditions -- approximately 30 to 300 nM ([@B5]), but may exceed 1 μM under more extreme conditions, such as mild hypoxia or strenuous exercise, and can reach up to several tens of micromolar concentration in severely traumatic situations, including local ischemia ([@B42]).

Adenosine triphosphate depletion and an increase of extracellular adenosine levels are positively correlated ([@B63]) and positively associated with sleep ([@B103]; [@B99]). Thus, adenosine may represent a state of relative energy deficiency. During spontaneous sleep/wake behavior in cats, adenosine levels in several brain regions are higher during SWS than wakefulness ([@B99], [@B98]). Moreover, *in vivo* microdialysis studies in cats revealed that adenosine concentrations increase 2-fold in the BF during a prolonged 6-h period of wakefulness compared with that at the beginning of sleep deprivation. Under more chronic sleep deprivation protocols, however, increases in adenosine concentrations during prolonged waking are no longer observed ([@B23]), suggesting that loss of the adenosine response may mark a shift from a homeostatic response to an allostatic response following reduced sleep.

Six decades after the discovery of adenosine's role in sleep, the mammalian brain cell types involved in the sleep-promoting effects of adenosine remain unclear ([@B37]). ATP, which is rapidly degraded to adenosine, and adenosine are released from glial cells and neurons. In genetically engineered mice in which the release of ATP is non-specifically blocked in astrocytes by selective expression of a dominant negative SNARE domain, decreased concentrations of extracellular adenosine are observed ([@B96]). While the amounts of wakefulness, SWS, and REM sleep in these mice are indistinguishable from those in wild-type mice, these mice exhibit reduced SWA and recovery sleep after sleep deprivation ([@B52]). Furthermore, reducing AdK in astrocytes, thereby increasing the adenosine tone, is sufficient to increase SWS-SWA and sleep consolidation, reduce the decrease in SWA across the light phase, and slow the decay of SWS-SWA within an average SWS episode, whereas selectively reducing AdK in neurons has no effect ([@B10]). These observations suggest that adenosine mediates the sleep deprivation-induced homeostatic sleep response. The source of the released adenosine, however, remains controversial. Some of the adenosine may originate from astrocytes and the majority may originate from neurons, but direct proof is lacking and thus the exact source of adenosine remains unknown. On the other hand, control of extracellular adenosine modulating sleep need clearly involves glial metabolism mediated by AdK ([@B10]).

[@B101] extensively investigated the effects of adenosine on wakefulness. They found that increasing the levels of adenosine in the central nervous system of rats by systemic administration of the ADA inhibitor deoxycoformycin led to increases in REM and SWS. In addition, [@B89] reported that focal administration of the ADA inhibitor coformycin into the rat TMN, where ADA is dominantly expressed, increases SWS, further supporting a hypnotic role for adenosine.

Effects of A~1~ Receptors and Sleep Homeostasis {#S3.SS2}
-----------------------------------------------

Adenosine acting through A~1~Rs facilitates sleep as non-selective and selective A~1~R agonists increase sleep and SWA ([@B102]; [@B8]), whereas A~1~R antagonists decrease sleep and SWA ([@B136]; [@B83]; [@B129]). Furthermore, A~1~R antagonism within the BF reduces the homeostatic sleep and SWA response following acute sleep deprivation ([@B50]). Conditional KO of A~1~Rs predominantly affecting forebrain glutamatergic neurons prevents sleep deprivation-induced increases in SWA, indicating that A~1~Rs are necessary for normal sleep homeostasis ([@B11]). In mixed background mice with constitutive KO of A~1~Rs, the normal sleep homeostatic response is maintained as measured by slow wave energy \[SWE; SWA (0.5--4.5 Hz) × time\] in SWS ([@B122]). Further, acute application of a selective A~1~R antagonist blocks the homeostatic response of increased SWS-SWA in sleep-deprived wild-type mice, but is ineffective in the constitutive KO mice under the same conditions ([@B122]). This finding suggests the presence of compensatory mechanisms in mice with constitutive KO that were not present in mice with conditional KO. Sleep facilitation via A~1~Rs occurs through inhibition of wake-active neurons in several brain areas, including both the brainstem and forebrain regions of the cholinergic arousal system \[mesopontine tegmentum ([@B103]) and BF ([@B1]; [@B130])\], and the lateral hypothalamus containing hypocretin/orexin neurons ([@B78]). Additionally, administration of a selective A~1~R agonist into the TMN decreases histamine in the frontal cortex while increasing sleep and SWA ([@B89]), suggesting that adenosine also inhibits activity of this wake-promoting neurotransmitter system. An additional mechanism by which adenosine facilitates sleep through A~1~Rs is by disinhibiting sleep-active neurons in the VLPO and anterior hypothalamic area ([@B21]; [@B84]). Finally, A~1~Rs mediate homeostatic sleep pressure based on astrocytic gliotransmission ([@B52]) and as part of a glial-neuronal circuit ([@B10]).

Prolonged waking through sleep deprivation increases the expression of A~1~Rs in both humans and rodents ([@B6]; [@B35]), with expression levels normalizing after recovery sleep in humans ([@B34]).

As mentioned above, SWA power is the primary indicator of homeostatic sleep need. SWA power reflects both the number of cells firing at SWA frequencies, which is an intrinsic feature of thalamocortical neurons ([@B82]; [@B29]), and the synchronicity of firing across neurons, which is a circuit effect involving cortical neurons, thalamocortical neurons, and neurons of the reticular nucleus of the thalamus ([@B123]). Activation of A~1~Rs influences SWA by both direct and indirect mechanisms; the direct mechanism is based on presynaptic inhibition of cortical and thalamic neurons, which results in relative functional deafferentation along with an A~1~R-induced increase in whole cell, GIRK channel conductance and decreased hyperpolarization activated currents (Ih), such that adenosine enhances slow oscillations in thalamocortical neurons ([@B94]). The indirect mechanism is a reduction of cholinergic tone by A~1~R-mediated inhibition of cholinergic arousal neurons ([@B103]; [@B99]). Acetylcholine inhibits slow oscillation in thalamocortical neurons ([@B24]; [@B124]; [@B81]); thus reduction of cholinergic tone is permissive for the expression of SWA.

Effects of A~2A~ Receptors and Control of Arousal {#S3.SS3}
-------------------------------------------------

Infusion of the selective A~2A~R agonist CGS21680 into the subarachnoid space below the ventral surface region of the rostral BF in rats or into the lateral ventricle of mice produces robust increases in SWS and REM sleep ([@B112]; [@B133]). *In vivo* microdialysis experiments, infusing CGS21680 into the BF dose-dependently decreases histamine release in the frontal cortex and medial preoptic area, and increases the release of GABA in the TMN, but not in the frontal cortex ([@B56]). Infusion of the GABA antagonist picrotoxin into the TMN attenuates the CGS21680-induced inhibition of histamine release, suggesting that the A~2A~R agonist induces sleep by inhibiting the histaminergic system through increasing the release of GABA in the TMN. Intracellular recordings of VLPO neurons in rat brain slices demonstrated that two distinct types of VLPO neurons exist in terms of their responses to serotonin and adenosine. VLPO neurons are inhibited by noradrenaline, acetylcholine, and an A~1~R agonist, whereas serotonin inhibits type-1 neurons, but excites type-2 neurons. An A~2A~R agonist post-synaptically excites type-2, but not type-1, neurons. These findings suggest that type-2 neurons are involved in initiating sleep, whereas type-1 neurons may contribute to sleep consolidation, because they are only activated in the absence of inhibitory effects from wake-inducing systems ([@B48]).

Administration of CGS21680 into the rostral BF, however, produces c-fos expression not only in the VLPO, but also within the NAc shell and the medial portion of the olfactory tubercle ([@B111]; [@B113]). Direct infusion of the A~2A~R agonist into the NAc induces SWS that corresponds to approximately 75% of the sleep amount measured when the A~2A~R agonist is infused into the subarachnoid space ([@B111]). This observation may indicate that activating A~2A~Rs within or close to the NAc induces sleep. Acting opposite to adenosine, caffeine, which is the most widely consumed psychostimulant in the world, enhances wakefulness because it acts to antagonize both A~1~R and A~2A~R subtypes. At doses commonly consumed by humans, caffeine partially (estimated as 25--50%) and non-selectively (similar affinity for both A~1~Rs and A~2A~Rs) blocks adenosine receptors ([@B44]). Experiments using mice with global genetic A~1~R and A~2A~R KO revealed that A~2A~Rs, but not A~1~Rs, mediate the wakefulness-inducing effect of caffeine ([@B58]), while single nucleotide mutations of the A~2A~R gene confer sensitivity to caffeine and sleep deprivation ([@B13]). The specific role of A~2A~Rs in the striatum was investigated in conditional A~2A~R KO mice based on the Cre/lox technology and local infection with AAV carrying short-hairpin RNA of the A~2A~R to silence the expression of the receptor. Selective deletion of the A~2A~Rs in the NAc shell blocked caffeine-induced wakefulness ([@B74]).

For caffeine to be effective as an A~2A~R antagonist, adenosine must tonically activate excitatory A~2A~Rs within the NAc shell. This activation likely occurs in the NAc shell because A~2A~Rs are abundantly expressed throughout the striatum, including the NAc shell and sufficient levels of adenosine are available under basal conditions ([@B107]; [@B127]). A recent study showed that chemogenetic or optogenetic activation of NAc A~2A~R core neurons projecting to the VP in the BF strongly induces SWS, whereas chemogenetic inhibition of these neurons prevents sleep induction, but does not affect homoeostatic sleep rebound ([@B92]). Interestingly, motivational stimuli suppress sleep and inhibit the activity of VP-projecting NAc A~2A~R neurons. In addition, another recent study revealed that adenosine is a plausible candidate molecule for activating NAc core A~2A~R neurons to induce SWS because elevated adenosine levels in the NAc core promote SWS via A~2A~Rs ([@B148]).

The sleep-gating ability of the NAc indirect pathway may explain the tendency toward falling asleep in boring situations. Interestingly, excessive daytime sleepiness is common in children with attention-deficit/hyperactivity disorder, who frequently start napping or daydream when they are bored ([@B140]). Dopamine produced by VTA neurons has a key role in processing reward, aversive, or cognitive signals ([@B142]; [@B19]; [@B116]), and projections from VTA dopaminergic neurons to the NAc, commonly known as the mesolimbic pathway, constitute a well-characterized reward circuit in the brain ([@B109]; [@B137]). Two independent studies recently examined the contribution of VTA dopaminergic neurons to wakefulness under baseline conditions by chemogenetic inhibition. One study found that chemogenetic inhibition of VTA dopamine neurons decreases the amount of wakefulness, thus suggesting that these neurons are necessary for baseline wakefulness in mice ([@B32]). The other study showed that chemogenetic inhibition of VTA dopamine neurons does not significantly affect wakefulness at baseline in mice ([@B91]). A plausible explanation for the differences in the observations in these studies is different ectopic Cre expression ([@B72]) in the midbrain of the tyrosine hydroxylase-Cre mice used by [@B32] or the dopamine transporter-Cre mice used by [@B91].

Unified Model of Sleep-Wake Regulation: Gating of Sleep Homeostasis by Arousal {#S4}
==============================================================================

As knowledge of the molecular and circuit bases of sleep/wake regulation expands, new roles of adenosine receptors in modulating different aspects of sleep emerge. For example, A~2A~Rs appear to promote sleep by suppressing arousal, whereas sleep need and the response to sleep deprivation are mediated by A~1~Rs, and these receptors may thus play a crucial role in the function of sleep. In light of the dissociable effects of adenosine for gating sleep and mediating sleep need at the receptor level, we propose a model of sleep-wake regulation in which the sleep state is regulated by arousal when an organism must consolidate wakefulness in response to environmental changes ([Figure 2](#F2){ref-type="fig"}). A typical example is motivated behavior that efficiently suppresses sleep of all stages and produces arousal by utilizing mesolimbic dopaminergic systems, whereas the wake state is suppressed in the absence of motivating stimuli by activation of A~2A~Rs in the NAc ([@B90]; [@B92]). The circadian and hypothalamic feeding systems have indirect influences by driving internally generated arousal, e.g., increasing motivation to forage according to the circadian phase. Thus in the absence of motivating/external arousing stimuli, the loss of the arousing influence of the circadian system (the sleep phase) may be sufficient to allow transition to sleep. On the other hand, sleep is necessary for SWS-SWA to facilitate the expression of sleep need and for the resolution of sleep need, a process in which A~1~Rs play a crucial role.

![Adenosine receptors influence sleep/wake behavior by modulating the arousal level through A~2A~Rs or A~1~Rs and the sleep need through A~1~Rs. Increased activity of the arousal centers promotes wakefulness. For example, activation of A~2A~Rs in the nucleus accumbens (NAc) and hypothalamus facilitates sleep through the inhibition of arousal-promoting neurons. The duration of wake time positively correlates with sleep need and the buildup of extracellular adenosine. The buildup of adenosine in the cortex and thalamus increases SWS-SWA through the activation of A~1~Rs. Sleep need also increases the probability of a state change from wake to sleep, primarily by decreasing arousal center activity (in part by activating A~1~Rs in arousal centers and A~2A~Rs in the NAc). The sleep state is permissive for sleep function that resolves the sleep need (as sleep function is accomplished), as reflected by the resolution of rebound SWS-SWA.](fnins-13-00740-g002){#F2}

Conclusion {#S5}
==========

Adenosine is a well-known somnogenic substance that affects normal sleep-wake patterns. While the source of the adenosine involved in sleep remains poorly understood, the metabolism of adenosine in the CNS is significantly mediated by adenosine kinase, which modulates the concentration of adenosine at neuronal A~1~R sites. Similarly, adenosine promotes sleep by several mechanisms in various locations via A~1~Rs or A~2A~Rs.

Adenosine receptor stimulation should be considered as a potential treatment for insomnia. Insomnia is a sleep disorder affecting millions of people around the world and frequently co-occurs with a wide range of psychiatric disorders ([@B108]; [@B25]; [@B117]). Although A~2A~R agonists strongly induce sleep, classical A~2A~R agonists have adverse cardiovascular effects and cannot be used clinically to treat sleep disorders. Moreover, the development of adenosine analogs for treating central nervous system disorders, including insomnia, is hampered by the poor transport of these drugs across the blood-brain barrier. A small blood brain barrier-permeable monocarboxylate was recently demonstrated to induce sleep by enhancing A~2A~R signaling in the brain, and surprisingly did not exhibit the typical cardiovascular effects of A~2A~R agonists ([@B65]). Therefore, molecules that allosterically enhance A~2A~R signaling could help people with insomnia fall asleep and may also be a potential treatment for psychiatric illness. Similarly, molecules that enhance A~1~R signaling might enhance sleep efficiency.
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